Therapeutic cancer vaccines were first developed 100 years ago and have remained broadly ineffective to date.

Before tangible results can be achieved, two major obstacles must be overcome.

Firstly, since tumour mutations are unique to each patient, cancer cell antigens must be targeted extremely precisely, which is very hard to achieve.

Secondly, a safe system is needed to deliver the vaccine to the right location and achieve a strong and specific immune response.

Li Tang's team at EPFL's School of Engineering is coming up with a solution to the delivery problem.

The researchers have used a polymerisation technique called polycondensation to develop a prototype vaccine that can travel automatically to the desired location and activate immune cells there.

The patented technique has been successfully tested in mice and is the topic of a paper appearing in ACS Central Science.

Li Tang has also co-founded a startup called PepGene, with partners that are working on an algorithm for quickly and accurately predicting mutated tumour antigens.

Together, the two techniques should result in a new and better cancer vaccine in the next several years.

Helping the body to defend itself

Most vaccines - against measles and tetanus for example - are preventive.

Healthy individuals are inoculated with weakened or inactivated parts of a virus, which prompt their immune systems to produce antibodies.

This prepares the body to defend itself against future infection.

However, the aim of a therapeutic cancer vaccine is not to prevent the disease, but to help the body defend itself against a disease that is already present.

"There are various sorts of immunotherapies other than vaccines, but some patients don't respond well to them. The vaccine could be combined with those immunotherapies to obtain the best possible immune response," explains Li Tang.

Another advantage is that vaccines should reduce the risk of relapse.

But how does it all work?

Avoiding getting lost in the blood stream

Delivering a cancer vaccine to the immune system involves various stages.

First, the patient is inoculated with the vaccine subcutaneously.

The vaccine will thus travel to the lymph nodes, where there are lots of immune cells.

Once there, the vaccine is expected to penetrate dendritic cells, which act as a kind of alert mechanism.

If the vaccine stimulates them correctly, the dendritic cells present specific antigens to cancer-fighting T-cells, a process that activates and trains the T-cells to attack them.

The procedure appears simple, but is extremely hard to put into practice.

Because they are very small, the components of a vaccine tend to disperse or be absorbed in the blood stream before reaching the lymph nodes.

To overcome that obstacle, Li Tang has developed a system that chemically binds the vaccine's parts together to form a larger entity.

The new vaccine, named Polycondensate Neoepitope (PNE), consists of neoantigens (mutated antigens specific to the tumour to be attacked) and an adjuvant.

When combined within a solvent, the components naturally bind together, forming an entity that is too large to be absorbed by blood vessels and that travels naturally to the lymph nodes.

Once inside a dendritic cell, the vaccine components separate again.

This enables the dendritic cell to present the right antigens to the T-cells, causing a powerful immune response.

"This new vaccine, combined with a highly advanced analysis of each patient's neoantigens, should allow cancer patients' immune systems to be activated in a personalised and safe way," says Li Tang.

The team is still perfecting the stage at which the tumour-specific antigens are detected.

"This identification stage is just as vital," concludes Li Tang. "Since these neoantigens aren't present in healthy cells, accurate identification will allow us to target tumour cells very precisely, without any toxicity in healthy tissue."

Source: EPFL